Shanghai Public Health Clinical Center
🇨🇳China
Clinical Trials
35
Active:1
Completed:6
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:4
Phase 2:2
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
Phase 4
9 (33.3%)Not Applicable
6 (22.2%)Phase 1
4 (14.8%)Phase 3
4 (14.8%)Early Phase 1
2 (7.4%)Phase 2
2 (7.4%)Prevelence of Liver Disease-Related Outcomes in People With HIV
Not yet recruiting
- Conditions
- MAFLDLiver FibrosisHIVMASHHepatic SteatosisMetabolic Syndrome X
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 320
- Registration Number
- NCT06940375
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis
Not Applicable
Not yet recruiting
- Conditions
- HIV/AIDS-associated Talaromycosis
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 116
- Registration Number
- NCT06926569
Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant
Early Phase 1
Not yet recruiting
- Conditions
- COVID - 19
- Interventions
- Biological: KFD1(0µg )Biological: KFD1(20µg)Biological: KFD1(40µg)Biological: KFD1(80µg)
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 60
- Registration Number
- NCT06768697
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center,Fudan University, Shanghai, Jinshan District, China
Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
Phase 4
Not yet recruiting
- Conditions
- Acquired Immunodeficiency Syndrome
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05493969
Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression
Phase 2
Recruiting
- Conditions
- HIV Infections
- Interventions
- Drug: ASC22 group
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 15
- Registration Number
- NCT05129189
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found